Friday, June 27, 2025 11:07:25 PM
dennisdave,
Agreed! How often have we seen regulator guidance changing over the years during the rise of DCVax-L to accommodate new modicum’s of treatment response, adequate measures and an actual pathway to advance their cell therapy? FDA has changed guidance, MHRA has changed guidance and others have learned to bend as well. This is all part of what I have referred to for years as sod busting and during this time manufacturing has been being brought up to speed from a point where Linda was pleading for help in 2018 to where we are now without any help from big pharma along the way. They had their chance to see and properly value what others were seeing back in 2012. Only Mr. Neil Woodford saw and bought into the vision with conviction but then the hope we all had that answers could come sooner never showed up as hoped for in that hoped for time frame and he got anxious, maybe even nudged by others and he got caught with his hands in the cookie jar and put in time out, his shares sold and NWBO nearly forced into bankruptcy.
Now, all these years later would be the perfect time for those with vision and ability to understand Linda’s plan to follow her lead and support the next steps to moving DCVax into patient accessibility after at least one regulator got their act together to make a way for DCVax. With this, I do expect Linda to lay out the plan forward and a system of accountability once approval occurs.
The lack of NWBO’s accountability to shareholders has to date and of certain necessity, not been a high priority to remedy because of all the outside influences on share price and timing of advances apart from Linda’s own very deliberate nature that reduces the risk of fatal mistakes for DCVax advancement. Linda had to scramble for ways to maintain investor interest in spite of the great length of time everything would take. We all came to know this as dangling carrots. Once any approval occurs the carrot dangling won’t be acceptable any longer. At that point it’s time for a plan and support in place to make it happen ; ). Best wishes.
Agreed! How often have we seen regulator guidance changing over the years during the rise of DCVax-L to accommodate new modicum’s of treatment response, adequate measures and an actual pathway to advance their cell therapy? FDA has changed guidance, MHRA has changed guidance and others have learned to bend as well. This is all part of what I have referred to for years as sod busting and during this time manufacturing has been being brought up to speed from a point where Linda was pleading for help in 2018 to where we are now without any help from big pharma along the way. They had their chance to see and properly value what others were seeing back in 2012. Only Mr. Neil Woodford saw and bought into the vision with conviction but then the hope we all had that answers could come sooner never showed up as hoped for in that hoped for time frame and he got anxious, maybe even nudged by others and he got caught with his hands in the cookie jar and put in time out, his shares sold and NWBO nearly forced into bankruptcy.
Now, all these years later would be the perfect time for those with vision and ability to understand Linda’s plan to follow her lead and support the next steps to moving DCVax into patient accessibility after at least one regulator got their act together to make a way for DCVax. With this, I do expect Linda to lay out the plan forward and a system of accountability once approval occurs.
The lack of NWBO’s accountability to shareholders has to date and of certain necessity, not been a high priority to remedy because of all the outside influences on share price and timing of advances apart from Linda’s own very deliberate nature that reduces the risk of fatal mistakes for DCVax advancement. Linda had to scramble for ways to maintain investor interest in spite of the great length of time everything would take. We all came to know this as dangling carrots. Once any approval occurs the carrot dangling won’t be acceptable any longer. At that point it’s time for a plan and support in place to make it happen ; ). Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
